Inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS), are chronic inflammatory disorders, leading to abdominal pain, diarrhea and motility disturbances.
In the gut endogenous fatty compounds play an important physiological role in gut homeostasis. Various enzymes, such as FAAH and FAAA are crucially involved in the modulation of physiological processes mediated by such fatty compounds in the gastrointestinal (GI) tract, and palmitoylethanolamide is one of the most important ones.
“In particular, for inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS), whose symptoms are based on chronic irritation and inflammation in the gut as well as on motility disorders, molecules as PEA may replace in future conventional therapies for IBD and IBS.”
The authors of a recent article: ‘Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract’ focus however unnecessary on new chemical enzyme inhibitors for reaching higher endogenous levels of the protective fatty compounds such as PEA. Because! Simple oral ingestion of PEA for instance as in PEA capsules replenishes the system and leads to the same goal, without side effects often dose-limiting for enzyme inhibitors.
“Palmitoylethanolamide is promising for the treatment of colitis. We prefer treatment either with the Italian PEA tablets, based on PEA-um or PEA-m, or by administrating the Dutch PEA capsules containing PEA-opt. Dutch capsules do not contain any chemical excipients and are 100% pure in vegetarian capsules.”
Advise for use of PEA
Only for these the Dutch and the Italian formulations long term safety and efficacy data gathered under the supervision of MDs are available. And only for these formulations (PEA-um, PEA-m and PEA-opt) there are currently data available proving that after intake PEA levels in the body significantly rise. Such data do not exist for me-too PEA formulations.
– See more at: http://puresupplements.info/ibd-and-ibs-palmitoylethanolamide-a-natural-treatment-focussing-on-gut-homeostasis/#sthash.Z02vlYRC.dpuf
Sałaga M, Sobczak M, Fichna J. Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract. Eur J Pharm Sci. 2013 Nov 22. pii: S0928-0987(13)00451-X. doi: 10.1016/j.ejps.2013.11.012.